valu usd unless otherwis note
make room iqvia tout next-gen
strength result
view deliv strong top bottom-lin result
compani continu see sale success next-gener cro sale
model investor may wait sever quarter though see
sale inflect faster revenu recognit earn growth
report result report ep vs
street revenu ebitda
ahead estim quarter featur
solid growth commerci solut revenu
 revenu grew constant-curr
declin in-lin expect compani also
provid guidanc rang guid ep rang
ebitda rang revenu
rang help currenc tailwind
wind back manag note ep beat
due below-the-lin item strong core perform
encourag outlook go forward fx tailwind led compani
rais revenu guidanc fy low high
end rang impli margin expans
guidanc support margin expans constant currenc
addit compani sign larg next-gen project
biopharma compani quarter along divers product
client-bas suggest abl withstand perhap gain
big pharma recent fear investor pharma servic
space book next-gen award sinc merger
reflect strength enterpris howev see book
translat faster revenu growth could take sever quarter year
given clinic trial durat push month averag
adjust estim adjust estim account
result updat outlook rais fy ep
reflect strength quarter rais
driven primarili beat rais revenu project
conjunct rais revenu guid year
maintain outperform maintain outperform rate share
trim price target reflect ep
estim trim target multipl reflect concern
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
iqvia creat octob merger
quintil im health busi oper
three segment research develop commerci
solut integr engag servic compani
provid outsourc real-world evid solut
biopharmaceut compani also provid solut
connect healthcar technology-en commerci
believ strateg benefit combin
two busi expect financi benefit
realiz time although like limit
increment benefit manag target
estim increment annual revenu growth
three year follow octob close
merger manag also expect achiev million
outperform rate believ
opportun deliv faster revenu growth cost
synergi fulli reflect share current
valuat believ share move higher compani
abl deliv better-than-expect cross-sal
valuat move higher reflect earn growth
sale cost-synergi project
bloomberg capit market estim upside/downside/target
price target share base price-to-earnings multipl
appli ep estim
modest premium share trade
sinc ipo slightli histor premium
 multipl believ premium
histor multipl justifi given synergi im
merger compani uniqu posit posit
view biopharma spend
upsid scenario price share
reflect ep ahead current estim
price-to-earnings multipl believ upsid could driven
stronger-than-expect cro revenu growth greater
cross-sal client well increas merger synergi
downsid scenario price share
reflect ep growth current forecast
ep growth price-to-earnings ratio line
histor price-to-earnings ratio share
iqvia hold result varianc tabl act commentscommerci solut expectationsresearch develop next-gen successintegr engag servic ebitda streamlin proceed ahead scheduledeprec tax eq tax equiti equiti earn iqvia net non- iqvia non- net non- average basic weight average dilut share buyback like lower iqvia hold inc
price target share base price-to-earnings multipl appli
ep estim modest premium share trade sinc
ipo slightli histor premium multipl believ
premium histor multipl justifi given synergi im merger
compani uniqu posit posit view biopharma spend price
target support outperform rate
risk rate price target
key risk biopharma spend trend execut merger integr project
sale cost synergi trend spend compani commerci solut
iqvia creat octob merger quintil im health
busi oper three segment research develop commerci solut
integr engag servic compani provid outsourc real-world
evid solut biopharmaceut compani compani also provid solut
connect healthcar technology-en commerci oper
revenu
revenu
sell gener administr
revenu
adjust estim conting consider
revenu
loss extinguish debt
incom incom tax equiti earn unconsolid affili
incom equiti earn unconsolid affili
equiti earn unconsolid affili
net incom attribut non-controlling interest
net incom attribut quintil transnat hold
sale busi
